Key facts
- It has raised $47.8M; the latest was Grant ($9.9M) in Mar 2025.
- Notable investors include Bpifrance, EQT Life Sciences, Takeda Ventures, Bioqube Ventures, Fund+ — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Egle Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Egle Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Egle Therapeutics
Operator of a biotechnology company intended to develop immunotherapies for oncology and autoimmune diseases. The company develops a proprietary Treg (T cells) modulating drug portfolio against a large pool of newly unveiled Treg targets as well as pioneering dis-engagement of tumor-infiltrating Tregs through a proprietary series of different variants featuring antagonism mechanism of action, enabling healthcare professionals to develop therapies targeting immune suppressor regulatory Tregs for treating cancer and other diseases.
- Sector
- Healthcare
- HQ
- Suresnes, France
- Founded
- 2020
- Employees
- 44
- Website
- egle-tx.com/
- Ownership
- Privately Held (backing)
Egle Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Egle Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Egle Therapeutics in its N-PORT filings yet. We sweep new filings monthly.